[The angiogenesis inhibitor vasostatin. In tumor inhibiting doses there is no impaired wound healing in the mouse model].
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D002135:Calcium-Binding Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D037282:Calreticulin; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D012261:Ribonucleoproteins / Q000009:adverse effects / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D002135:Calcium-Binding Proteins; D037282:Calreticulin; D010446:Peptide Fragments; D012261:Ribonucleoproteins; C121986:vasostatin